PL440687A1 - Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3 - Google Patents

Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3

Info

Publication number
PL440687A1
PL440687A1 PL440687A PL44068722A PL440687A1 PL 440687 A1 PL440687 A1 PL 440687A1 PL 440687 A PL440687 A PL 440687A PL 44068722 A PL44068722 A PL 44068722A PL 440687 A1 PL440687 A1 PL 440687A1
Authority
PL
Poland
Prior art keywords
treatment
molecular weight
spinocerebellar ataxia
low molecular
ataxia type
Prior art date
Application number
PL440687A
Other languages
English (en)
Other versions
PL247748B1 (pl
Inventor
Maciej FIGIEL
Piotr PIASECKI
Kalina WIATR
Original Assignee
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Chemii Bioorganicznej Polskiej Akademii Nauk filed Critical Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Priority to PL440687A priority Critical patent/PL247748B1/pl
Priority to EP23722102.3A priority patent/EP4493205A1/en
Priority to PCT/PL2023/050017 priority patent/WO2023177314A1/en
Publication of PL440687A1 publication Critical patent/PL440687A1/pl
Publication of PL247748B1 publication Critical patent/PL247748B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3, przy czym związek ten jest wybrany spośród bortezomibu, karfilzomibu, VLX1570 lub oprozomibu.
PL440687A 2022-03-18 2022-03-18 Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3 PL247748B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL440687A PL247748B1 (pl) 2022-03-18 2022-03-18 Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3
EP23722102.3A EP4493205A1 (en) 2022-03-18 2023-03-17 A low molecular weight compound for use in the treatment of spinocerebellar ataxia type 3
PCT/PL2023/050017 WO2023177314A1 (en) 2022-03-18 2023-03-17 A low molecular weight compound for use in the treatment of spinocerebellar ataxia type 3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL440687A PL247748B1 (pl) 2022-03-18 2022-03-18 Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3

Publications (2)

Publication Number Publication Date
PL440687A1 true PL440687A1 (pl) 2023-09-25
PL247748B1 PL247748B1 (pl) 2025-08-25

Family

ID=86329479

Family Applications (1)

Application Number Title Priority Date Filing Date
PL440687A PL247748B1 (pl) 2022-03-18 2022-03-18 Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3

Country Status (3)

Country Link
EP (1) EP4493205A1 (pl)
PL (1) PL247748B1 (pl)
WO (1) WO2023177314A1 (pl)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937005A1 (en) * 2005-03-22 2006-09-28 President And Fellows Of Harvard College Treatment of protein degradation disorders

Also Published As

Publication number Publication date
PL247748B1 (pl) 2025-08-25
EP4493205A1 (en) 2025-01-22
WO2023177314A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
NO20083207L (no) Inhibitorer av IAP
MX2025003905A (es) Tiosulfato de sodio anhidro y formulaciones de este
ATE433447T1 (de) Pyrimiidinverbindungen
EP4186506A4 (en) Composition containing arylamide derivative
NO20052626L (no) Middel for forhindring eller behandling av neuropati
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
ATE173459T1 (de) Alifatische propargylamine als selektive mao-b inhibitoren und als neuroprotektive agenzien
EA201000329A1 (ru) Циклические депсипептиды
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
PY1909009A (es) Compuestos naftaleno isoxazolina para controlar plagas invertebradas
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
EP1755576A4 (en) ANTIMICROBIAL COMPOSITIONS AND METHOD OF USE THEREOF
MX2025002166A (es) Compuestos y metodos para modular her2
PL440687A1 (pl) Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3
MX2023009677A (es) Inhibidores de enzimas.
MX2021000691A (es) Compuestos de isoxazolina para el control de plagas de invertebrados.
MX2020013518A (es) Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) del receptor de acido gamma-aminobutirico a alfa5 (gaba a alfa5).
ATE346040T1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
CO2025004541A2 (es) Insecticidas de pirazolamida
FR3075619B1 (fr) Derives xylosides de resveratrol pour leur utilisation en cosmetique